Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia
The elderly patients with acute myeloid leukemia(AML)usually carry unfavorable molecular and cytogenetic abnormalities.Allogeneic hematopoietic stem cell transplantation has been increasingly used in elderly AML patients,and the 5-year survival rate is significantly higher than that of chemotherapy group.Recently,do-mestic guidelines have raised the age limit of allogeneic transplantation for elderly AML patients to 65 years old,and non-myeloablative allogeneic transplantation can also be carried out for some eligible elderly AML patients younger than 70 years old.Age ≥60 years,HCT-CI≥2,relapsed or refractory diseases,especially age ≥70 years,HCT-CI≥6,more times of relapsing and CR3,are associated with higher risk of death.The proportion of domestic elderly AML patients receiving allogeneic transplantation is far lower than that of foreign data,and transplantation in elderly AML patients still faces great social needs and development potential.Further optimiza-tion of pre-transplant induction therapy,introduction of low-toxicity and high-efficiency targeted drugs,further reduction of conditioning toxicity and improvement of post-transplant management will help to improve long-term survival rate and reduce transplant-related mortality and cumulative incidence of relapse.
NETL
NSTL
万方数据
